PanGen Biotech Inc (222110) - Total Assets
Based on the latest financial reports, PanGen Biotech Inc (222110) holds total assets worth ₩32.76 Billion KRW (≈ $22.20 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check PanGen Biotech Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
PanGen Biotech Inc - Total Assets Trend (2014–2024)
This chart illustrates how PanGen Biotech Inc's total assets have evolved over time, based on quarterly financial data. Explore PanGen Biotech Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
PanGen Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
PanGen Biotech Inc's total assets of ₩32.76 Billion consist of 68.0% current assets and 32.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.43 Billion | 0.0% |
| Accounts Receivable | ₩3.01 Billion | 9.9% |
| Inventory | ₩6.00 Billion | 19.7% |
| Property, Plant & Equipment | ₩5.81 Billion | 19.0% |
| Intangible Assets | ₩3.41 Billion | 11.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how PanGen Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 222110 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PanGen Biotech Inc's current assets represent 68.0% of total assets in 2024, an increase from 23.9% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 14.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 19.7% of total assets.
PanGen Biotech Inc Competitors by Total Assets
Key competitors of PanGen Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
PanGen Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.52 | 3.30 | 1.20 |
| Quick Ratio | 6.01 | 1.77 | 1.01 |
| Cash Ratio | 0.00 | 0.46 | 0.00 |
| Working Capital | ₩20.60 Billion | ₩10.62 Billion | ₩4.00 Billion |
PanGen Biotech Inc - Advanced Valuation Insights
This section examines the relationship between PanGen Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 47.3% |
| Total Assets | ₩30.54 Billion |
| Market Capitalization | $44.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values PanGen Biotech Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PanGen Biotech Inc's assets grew by 47.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PanGen Biotech Inc (2014–2024)
The table below shows the annual total assets of PanGen Biotech Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩30.54 Billion ≈ $20.70 Million |
+47.27% |
| 2023-12-31 | ₩20.74 Billion ≈ $14.06 Million |
+0.33% |
| 2022-12-31 | ₩20.67 Billion ≈ $14.01 Million |
-52.23% |
| 2021-12-31 | ₩43.28 Billion ≈ $29.33 Million |
+19.19% |
| 2020-12-31 | ₩36.31 Billion ≈ $24.61 Million |
-7.10% |
| 2019-12-31 | ₩39.08 Billion ≈ $26.49 Million |
-14.31% |
| 2018-12-31 | ₩45.61 Billion ≈ $30.91 Million |
+28.14% |
| 2017-12-31 | ₩35.59 Billion ≈ $24.12 Million |
-4.83% |
| 2016-12-31 | ₩37.40 Billion ≈ $25.34 Million |
+135.22% |
| 2015-12-31 | ₩15.90 Billion ≈ $10.77 Million |
-5.77% |
| 2014-12-31 | ₩16.87 Billion ≈ $11.43 Million |
-- |
About PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more